PMID- 21715491
OWN - NLM
STAT- MEDLINE
DCOM- 20111004
LR  - 20211020
IS  - 1098-5514 (Electronic)
IS  - 0022-538X (Print)
IS  - 0022-538X (Linking)
VI  - 85
IP  - 17
DP  - 2011 Sep
TI  - Human leukocyte antigen variants B*44 and B*57 are consistently favorable during 
      two distinct phases of primary HIV-1 infection in sub-Saharan Africans with 
      several viral subtypes.
PG  - 8894-902
LID - 10.1128/JVI.00439-11 [doi]
AB  - As part of an ongoing study of early human immunodeficiency virus type 1 (HIV-1) 
      infection in sub-Saharan African countries, we have identified 134 seroconverters 
      (SCs) with distinct acute-phase (peak) and early chronic-phase (set-point) 
      viremias. SCs with class I human leukocyte antigen (HLA) variants B*44 and B*57 
      had much lower peak viral loads (VLs) than SCs without these variants (adjusted 
      linear regression beta values of -1.08 +/- 0.26 log(10) [mean +/- standard error] and 
      -0.83 +/- 0.27 log(10), respectively; P < 0.005 for both), after accounting for 
      several nongenetic factors, including gender, age at estimated date of infection, 
      duration of infection, and country of origin. These findings were confirmed by 
      alternative models in which major viral subtypes (A1, C, and others) in the same 
      SCs replaced country of origin as a covariate (P </= 0.03). Both B*44 and B*57 were 
      also highly favorable (P </= 0.03) in analyses of set-point VLs. Moreover, B*44 was 
      associated with relatively high CD4(+) T-cell counts during early chronic 
      infection (P = 0.02). Thus, at least two common HLA-B variants showed strong 
      influences on acute-phase as well as early chronic-phase VL, regardless of the 
      infecting viral subtype. If confirmed, the identification of B*44 as another 
      favorable marker in primary HIV-1 infection should help dissect mechanisms of 
      early immune protection against HIV-1 infection.
FAU - Tang, Jianming
AU  - Tang J
AD  - Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 
      USA.
FAU - Cormier, Emmanuel
AU  - Cormier E
FAU - Gilmour, Jill
AU  - Gilmour J
FAU - Price, Matthew A
AU  - Price MA
FAU - Prentice, Heather A
AU  - Prentice HA
FAU - Song, Wei
AU  - Song W
FAU - Kamali, Anatoli
AU  - Kamali A
FAU - Karita, Etienne
AU  - Karita E
FAU - Lakhi, Shabir
AU  - Lakhi S
FAU - Sanders, Eduard J
AU  - Sanders EJ
FAU - Anzala, Omu
AU  - Anzala O
FAU - Amornkul, Pauli N
AU  - Amornkul PN
FAU - Allen, Susan
AU  - Allen S
FAU - Hunter, Eric
AU  - Hunter E
FAU - Kaslow, Richard A
AU  - Kaslow RA
CN  - IAVI African HIV Research Network
LA  - eng
GR  - 2D43 TW001042/TW/FIC NIH HHS/United States
GR  - K02 AI076123/AI/NIAID NIH HHS/United States
GR  - R01 AI071906/AI/NIAID NIH HHS/United States
GR  - MC_U950080930/MRC_/Medical Research Council/United Kingdom
GR  - R01 AI064060/AI/NIAID NIH HHS/United States
GR  - D43 TW001042/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20110629
PL  - United States
TA  - J Virol
JT  - Journal of virology
JID - 0113724
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Adult
MH  - Africa South of the Sahara
MH  - CD4 Lymphocyte Count
MH  - Female
MH  - HIV Infections/*immunology/virology
MH  - HIV-1/*immunology/pathogenicity
MH  - HLA-B Antigens/genetics/*immunology
MH  - Humans
MH  - Immunity, Innate
MH  - Male
MH  - Middle Aged
MH  - *Viral Load
PMC - PMC3165830
EDAT- 2011/07/01 06:00
MHDA- 2011/10/05 06:00
PMCR- 2012/03/01
CRDT- 2011/07/01 06:00
PHST- 2011/07/01 06:00 [entrez]
PHST- 2011/07/01 06:00 [pubmed]
PHST- 2011/10/05 06:00 [medline]
PHST- 2012/03/01 00:00 [pmc-release]
AID - JVI.00439-11 [pii]
AID - 0439-11 [pii]
AID - 10.1128/JVI.00439-11 [doi]
PST - ppublish
SO  - J Virol. 2011 Sep;85(17):8894-902. doi: 10.1128/JVI.00439-11. Epub 2011 Jun 29.